Augpac/Augpac Injection Special Precautions

Augpac: Transient hepatitis and cholestatic jaundice has been reported hence, Amoxicillin and clavulanate potassium should be used with caution in patients with evidence of hepatic dysfunction.
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with any penicillin, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other allergens. If an allergic reaction occurs, Amoxicillin and clavulanate potassium should be discontinued and the appropriate therapy instituted: adrenaline, corticosteroids and antihistamines.
Effects on the Ability to Drive or Operate Machinery: 375 mg & 625 mg tablet: Patients experiencing dizziness or other central nervous disturbances, including visual disturbances, should not drive or operate machinery.
Augpac Injection: Before starting therapy with amoxicillin sodium and clavulanate potassium for injection, previous hypersensitivity reactions (e.g. penicillin hypersensitivity) should be enquired.
Use amoxicillin sodium and clavulanate potassium for injection with caution in patients with hepatic dysfunction and dosage adjustment should be made in patients with kidney dysfunction.
Amoxicillin sodium and clavulanate potassium for injection cannot be used for intramuscular administration.
Amoxicillin sodium and clavulanate potassium for injection is less stable in infusions containing glucose, dextran or bicarbonate.